What were the main findings from the estrogen plus progestin and colorectal cancer analyses?
Fewer women who took estrogen plus progestin (E+P) developed colorectal cancer than women taking placebo (inactive pills). The cancer cases found in women taking E+P had similar characteristics (looked the same under the microscope) but the tumors had spread more throughout the body than those in the placebo group.